Addiction recovery is not only feasible, but it also happens frequently. Stopping a substance's use is the first step towards recovery. Even that behaviour is unfathomable for many addicts. Even so, it's only the first step. The process of behaviour modification, by which the brain progressively renews and rewires itself, must come next. That procedure might take many months or longer. And there are several methods to do it. There is no agreed-upon definition of recovery and no scientific tests that can measure it. According to many specialists, the main characteristics of an addictive condition include addictive substances use that persists despite negative effects and the emergence of cravings accompanied by an inability to regulate usage. As a result of prolonged substance abuse, addiction gradually takes shape because drugs alter the brain's reaction to rewards and impair the ability to suppress drug cravings. Recovery, which is a mechanism in which brain cells progressively regain the capability to respond to natural origin of pleasure and reestablish control over the need to use, always requires time. The end of detrimental consequences on oneself is another often used metric of healing.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States